This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Anti Ischemic Effects of Abciximab in Angioplasty and Stenting Patients (AIR)

This study has been completed.
Information provided by (Responsible Party):
Kreton Mavromatis, MD, FACC, Emory University Identifier:
First received: September 19, 2006
Last updated: September 11, 2013
Last verified: September 2013


TITLE: Anti-Ischemic effects of Abciximab(Reopro)

PATIENT POPULATION: Patients undergoing PCI(an interventional procedure placing a small stent/metallic tube to keep a narrowed artery in your heart open) and either on a stable statin dose or not on a statin. Statin= cholesterol lowering drug(ie, lipitor, zocor).

INTERVENTION: Heparin vs. heparin + abciximab during PCI

PURPOSE: Measure the effects of abciximab on special healing blood stem cells (EPC's-Endothelial Progenitor Cells), on inflammation, on oxidative stress and on microvascular blood flow.


  1. 50ccs blood draw on day 1(from sheath), day 2 ,day 7 and day 28.
  2. Measurement of blood flow in selected suitable patients
  3. 10 minute questionnaire before discharge and on visit on day 28.

Condition Intervention Phase
Coronary Artery Disease Drug: Abciximab Phase 4

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Anti Ischemic Effects of Abciximab in Angioplasty and Stenting Patients (AIR)

Resource links provided by NLM:

Further study details as provided by Kreton Mavromatis, MD, FACC, Emory University:

Enrollment: 220
Study Start Date: January 2003
Study Completion Date: December 2009
Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Abciximab
    Other Name: Reopro

Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Subjects with coronary artery disease undergoing left heart catheterization

Inclusion Criteria:

  1. Have either:

    • clinical history of anginal symptoms or positive stress test or
    • in stent restenosis
  2. Have an angiographic >70% coronary artery stenosis that will be treated with coronary angioplasty or stenting procedure
  3. For at least four weeks prior to the procedure have been on, no Hmgcoa- reductase inhibitor or a stable statin dose
  4. negative pregnancy test
  5. are able to give informed consent

Exclusion Criteria:

  1. Coronary intervention within four weeks prior to enrollment.
  2. Treatment with abciximab antagonist within four weeks.
  3. treatment with thrombolytic therapy within 48 hours
  4. MI within 2 months.
  5. recent infections
  6. general anesthesia within 3 months.
  7. renal failure
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00379418

United States, Georgia
Atlanta VA Medical Center
Atlanta, Georgia, United States, 30033
Emory University Hospital
Atlanta, Georgia, United States, 30322
Sponsors and Collaborators
Emory University
Principal Investigator: Arshed A Quyyumi, M.D. EUH
  More Information

Responsible Party: Kreton Mavromatis, MD, FACC, Assistant Professor, Emory University Identifier: NCT00379418     History of Changes
Other Study ID Numbers: IRB00021864
Study First Received: September 19, 2006
Last Updated: September 11, 2013

Additional relevant MeSH terms:
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Heart Diseases
Cardiovascular Diseases
Arterial Occlusive Diseases
Vascular Diseases
Antibodies, Monoclonal
Immunoglobulin Fab Fragments
Platelet Aggregation Inhibitors
Immunologic Factors
Physiological Effects of Drugs processed this record on September 21, 2017